浙江东方基因生物制品股份有限公司 2025 年第三季度报告 证券代码：688298 证券简称：东方生物 浙江东方基因生物制品股份有限公司 2025 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会及董事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假记载、误 导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第三季度财务报表是否经审计 □是√否 （一） 主要会计数据和财务指标 单位：元 币种：人民币 | | | 本报告期比 | | 年初至报告期 | | --- | --- | --- | --- | --- | | 项目 | 本报告期 | 上年同期增 | 年初至报告期末 | 末比上年同期 | | | | 减变动幅度 | | 增减变动幅度 | | | | (%) | | (%) | | 营业收入 | 268,732,265.94 | 12.26 | 671,812, ...

东方生物公告，第三季度营收为2.69亿元，同比增长12.26%；净利润亏损4953.43万元，同比增长 55.19%。前三季度营收为6.72亿元，同比增长2.16%；净利润亏损2.13亿元，同比增长18.89%。 ...

Group 1 - The core point of the article is that Dongfang Biological has recently obtained medical device registration certificates for several time-resolved fluorescence immunoassay products in multiple countries, including the EU, Colombia, Indonesia, and Saudi Arabia [1] - The products include the "Calprotectin Quantitative Detection Kit" among others [1] - For the fiscal year 2024, the revenue composition of Dongfang Biological is projected to be 97.99% from the in vitro diagnostic industry and 2.01% from other businesses [1] - As of the report, Dongfang Biological has a market capitalization of 5.1 billion yuan [1]

证券代码：688298 证券简称：东方生物 公告编号：2025-054 浙江东方基因生物制品股份有限公司 关于自愿披露获得医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上述取证产品为荧光免疫系列检测产品，采用时间分辨荧光免疫技术（TRFIA）， 利用稀土元素长荧光寿命特性，通过时间延迟测量与波长分辨技术消除非特异性 荧光干扰，可适用于复杂样本、超微量物质检测，具有高灵敏度，抗干扰能力强， 操作便捷，即使快速定量检测、仪器半自动/自动分析等优势，适用于炎症检测、 心肌检测、甲状腺功能检测、糖尿病检测、肾功能检测、贫血检测等领域的临床 辅助诊断，进一步完善了公司在免疫诊断技术平台的技术路径及产品系列，从定 性检测到定量检测，在欧盟市场的基数上，拓展了哥伦比亚、印度尼西亚、沙特 等可销售国家，有利于国际市场的整体拓展。 三、风险提示 | 产品名称 | | | | | 持证公 | | --- | --- | --- | --- | --- | --- | | （中文） | 证书编号 | 适用国家 | 预期用 ...

Group 1: Industry Overview - Over 20 companies in the semiconductor and computing power sectors have been intensively researched by institutions since October, indicating a sustained positive industry outlook and strong market demand [1] - The storage industry is experiencing high prosperity driven by the restructuring of supply and demand due to the AI wave, with companies like Shanghai Beiling and Demingli reporting positive market expectations and product advancements [1][2] Group 2: Storage Sector Developments - Shanghai Beiling has launched new EEPROM products for automotive applications and introduced NOR Flash and DDR5 memory SPD chip products, enhancing its storage chip portfolio [1] - Demingli is witnessing an overall price increase in the storage market and has successfully integrated its products into the supply chains of major internet and server manufacturers, leading to rapid business growth [1][2] - Hengshuo Co. is optimistic about the NOR Flash market, expecting price increases in Q4 due to favorable market conditions and is actively developing advanced NOR Flash products [2] - Huicheng Co. plans to invest strategically in Xin Feng Technology to expand its DRAM packaging capacity, aiming to benefit from the growth of leading storage chip manufacturers [3] Group 3: Computing Power Market Insights - The demand for computing power remains strong, with companies like Haiguang Information reporting a 69.60% year-on-year revenue growth, reaching 4.026 billion yuan in Q3 2025 [4] - Haiguang Information has a contract liability of 2.8 billion yuan, indicating robust customer order demand, and has adjusted its inventory to align with market needs [5] - Chip Origin Co. anticipates a significant increase in new orders, with a projected 145.80% year-on-year growth, driven largely by AI-related orders [5] - Shunwang Technology has developed a stable and efficient computing power service capability, successfully launching innovative products to meet diverse computing needs [6] - Guangmai Technology has collaborated on a domestic computing power cluster project, achieving significant results and positive feedback from major internet companies [6]

Core Insights - The company, Oriental Bio, reported a decline in revenue and net profit for the first half of 2025, indicating ongoing financial challenges [1] - In 2024, the company experienced a slight increase in revenue but a significant increase in net losses compared to the previous year [2] Financial Performance - In the first half of 2025, Oriental Bio achieved operating revenue of 403 million yuan, a year-on-year decrease of 3.62% [1] - The net profit attributable to shareholders was -163 million yuan, compared to -152 million yuan in the same period last year [1] - The net profit after deducting non-recurring gains and losses was -184 million yuan, an improvement from -207 million yuan year-on-year [1] - The net cash flow from operating activities was -123 million yuan, an improvement from -332 million yuan in the previous year [1] 2024 Financial Overview - In 2024, the company reported operating revenue of 828 million yuan, a year-on-year increase of 0.95% [2][3] - The net profit attributable to shareholders was -529 million yuan, a significant increase in losses compared to -398 million yuan in the previous year, reflecting a 33.06% decline [2][3] - The net profit after deducting non-recurring gains and losses was -571 million yuan, also a significant increase in losses compared to -431 million yuan in the previous year, reflecting a 32.60% decline [2][3] - The net cash flow from operating activities was -348 million yuan, an improvement from -1.646 billion yuan in the previous year [2] Fundraising and Use of Proceeds - Oriental Bio raised a total of 637.5 million yuan from its issuance, with a net amount of 550.8 million yuan after expenses [4] - The final net amount raised was 10.82 million yuan less than originally planned [4] - The funds are intended for projects including the production of rapid diagnostic products, technology research and development, marketing network construction, and working capital [4][5]

Core Insights - Oriental Bio has successfully registered its self-developed nucleic acid joint detection reagent for COVID-19 and influenza viruses with the National Medical Products Administration (NMPA) in China, enhancing its product portfolio in respiratory diagnostics [1] - The company has established a dual-market strategy focusing on both domestic and international markets, along with a parallel approach for professional testing and home self-testing [1][9] Technology Platforms - Oriental Bio has developed three core technology platforms: immunodiagnostic platform, nucleic acid testing platform, and liquid chip technology platform, each catering to different detection needs [2] - The immunodiagnostic platform offers rapid results in as little as 15 minutes, suitable for home testing and primary healthcare settings [2] - The nucleic acid testing platform emphasizes high sensitivity, meeting the diagnostic needs of medical institutions [2] - The liquid chip technology platform supports multiplex testing, allowing for the simultaneous identification of multiple respiratory pathogens [2] Product Pipeline - The company has created a diverse product pipeline for respiratory diagnostics, covering common pathogens like COVID-19, influenza A and B, and other viruses such as RSV and adenovirus [3] - Products include rapid test kits that do not require instruments and high-sensitivity nucleic acid tests, as well as multiplex tests that can detect up to nine pathogens simultaneously [3] Global Certifications - Oriental Bio has achieved significant global certifications, including 66 EU CE IVDR registrations, 6 US FDA registrations, and 16 NMPA registrations, making it one of the leading companies in respiratory diagnostics with global certifications [4] - Notable products include self-testing kits for influenza A and B that have received both EU IVDR and NMPA certifications, enabling dual-market circulation [4] - The COVID-19 and influenza joint detection self-testing kit has received both EU IVDR and FDA De Novo certifications, marking it as a pioneering product in the US market [4] Market Expansion - The year 2025 is identified as a critical year for Oriental Bio's overseas market expansion, with recent approvals for new products in Europe, New Zealand, and Brazil [7] - The company has successfully penetrated major global markets, including Europe, North America, South America, Oceania, the Middle East, and Southeast Asia [7] Dual-Line Strategy - Oriental Bio employs a dual-line strategy, offering both professional and self-testing versions of its products, which enhances market coverage [9] - The company has successfully entered mainstream retail channels in the US, significantly expanding its consumer reach [9] - As of now, Oriental Bio has obtained certifications for over 130 products related to various respiratory pathogens, establishing a leading position in the global respiratory diagnostics market [9]

Core Viewpoint - Zhejiang Oriental Gene Biological Products Co., Ltd. has obtained registration certificates for several medical device products, enhancing its product offerings in HPV virus detection and respiratory virus testing [1][2]. Group 1: Medical Device Registration - The company’s subsidiary, Hangzhou Danwei Biotechnology Co., Ltd., has received registration certificates for 14 types of high-risk HPV nucleic acid detection and 16/18 typing reagents in China, expanding the company's product range for HPV virus detection [1]. - Additionally, the company has obtained registration for COVID-19 and influenza A/B virus nucleic acid co-detection reagents, further improving its portfolio in respiratory combined detection products [1]. Group 2: Impact on the Company - The new product registrations are expected to broaden the company's sales offerings in molecular diagnostic technology, facilitating overall market expansion in China [1].

Core Points - The company Dongfang Bio announced that its subsidiary Hangzhou Danwei Biotechnology Co., Ltd. has recently obtained registration certificates for several medical device products [2] Group 1 - The registered products include a kit for detecting 14 high-risk types of human papillomavirus (HPV) nucleic acid and a combined nucleic acid detection kit for COVID-19 and influenza A and B viruses, both using fluorescent PCR method [2]

Group 1 - Xinxiang Chemical Fiber will suspend production for approximately 90 days starting October 1, 2025, affecting an annual capacity of 31,200 tons, resulting in a revenue decrease of approximately 185 million yuan and a profit reduction of about 48 million yuan [1] - Bozhong Precision plans to transfer 18.29% of its stake in Suzhou Linghou Robot for 64 million yuan, retaining a 21.61% ownership post-transaction [1] - Haixing Electric is a recommended candidate for a State Grid procurement project, with an expected bid amount of approximately 128 million yuan [2] Group 2 - Samsung Medical is a recommended candidate for multiple State Grid procurement projects, with a total expected bid amount of approximately 193 million yuan [2][3] - Youxunda is a recommended candidate for a State Grid procurement project, with a bid amount of approximately 107 million yuan, representing 10.55% of its 2024 revenue [3] - Tiancheng Self-Control has received a notification for a seat assembly project from a well-known domestic new energy vehicle company, expected to start mass production in June 2026 [4] Group 3 - YKYY013 injection has received FDA approval for clinical trials to treat chronic hepatitis B virus infection [4] - Pulaide has signed a strategic cooperation agreement with an international electric tool brand, with a total procurement amount exceeding 700 million yuan over five years [4] - Sichuan Shuangma's subsidiary has obtained GMP certification from Russia, covering core aspects of drug quality and production systems [6] Group 4 - Boshi Co. has signed an industrial service contract worth approximately 96.99 million yuan with Guoneng Baotou Coal Chemical [7] - Wansheng Intelligent is a recommended candidate for a State Grid project, with an expected bid amount of approximately 67.98 million yuan, representing 7.25% of its 2024 revenue [9][10] - Huazi Industrial plans to sell its dairy farm assets for 38.5 million yuan, expecting a positive impact of approximately 11.7 million yuan on its current profits [10] Group 5 - Jinguang Electric has won a State Grid project with a total bid amount of approximately 28.4 million yuan, accounting for 3.82% of its 2024 revenue [11] - Nanjiao Food reported a net profit of 10,410 yuan for August, a year-on-year decrease of 98.31% [13] - Dongfang Bio's subsidiary has obtained registration certificates for two medical device products [15] Group 6 - Lanhua Kecai has signed a strategic cooperation agreement with Shanghai Pangu Power to promote intelligent and efficient transformation in the coal mining industry [17] - Yabao Pharmaceutical has decided to terminate the SY-009 research project, with a total investment of approximately 87.87 million yuan to be fully impaired [18] - Tian Shili's subsidiary has received approval for a new indication for its recombinant human urokinase injection for acute ischemic stroke treatment [20] Group 7 - Su Yan Jingshen's executives plan to increase their shareholding in the company, with a total investment of between 1.9 million and 2.66 million yuan [22] - Baiyun Electric and its subsidiary have won a State Grid project with a total bid amount of approximately 162 million yuan, covering multiple equipment types [23] - China West Electric's director has resigned due to work reasons, effective September 19, 2025 [25] Group 8 - Jianan Intelligent is a recommended candidate for a State Grid project with a total expected bid amount of approximately 73.12 million yuan [26] - Juhua Technology is a recommended candidate for a State Grid project with a total expected bid amount of approximately 142 million yuan [27] - Tengyuan Cobalt's actual controller has committed not to reduce holdings for the next 12 months, holding 37.89% of the total shares [28] Group 9 - Changfei Optical Fiber announced that Draka Comteq B.V. no longer holds H shares in the company after selling 37.59 million shares [28] - Mongcao Ecological's subsidiary has signed a contract for an ecological restoration project worth 225.2 million yuan [29] - Weiao Co. plans to distribute a cash dividend of 0.1 yuan per share, totaling approximately 39.29 million yuan [30]